Clotrimazole 1% Topical Antifungal Cream

Dosage varies significantly based on the formulation and the condition being treated. According to clinical guidelines:

• Tinea Pedis, Tinea Cruris, and Tinea Corporis: Apply a thin layer of 1% cream or solution to the affected and surrounding skin area twice daily (morning and evening). Treatment duration typically lasts 2 weeks for jock itch and 4 weeks for athlete's foot or ringworm.
• Vulvovaginal Candidiasis:
• 1% Vaginal Cream: One applicatorful (approx. 5g) daily at bedtime for 7 consecutive days.
• 2% Vaginal Cream: One applicatorful daily at bedtime for 3 consecutive days.
• Vaginal Tablets: 100mg for 7 days, 200mg for 3 days, or a single 500mg dose, depending on the specific product and severity.
• Oropharyngeal Candidiasis (Thrush): One 10mg troche dissolved slowly in the mouth five times daily for 14 consecutive days.
• Prophylaxis of Thrush: One 10mg troche three times daily for the duration of chemotherapy or until the patient is no longer at risk.

• Topical Use: Clotrimazole is generally considered safe for children over the age of 2 for tinea infections. For diaper dermatitis (diaper rash) caused by Candida, it may be used in infants under medical supervision.
• Oral Troche: Safety and efficacy in children under the age of 3 have not been established. Use in older children should be monitored to prevent choking.
• Vaginal Use: Not typically recommended for girls under 12 years of age unless directed by a physician, as vaginal symptoms in this age group may indicate other underlying issues.

Renal Impairment

Because systemic absorption of topical and vaginal clotrimazole is minimal, no dosage adjustments are generally required for patients with kidney disease. For oral troches, renal adjustment is also typically unnecessary due to hepatic metabolism.

Hepatic Impairment

Patients with severe liver impairment should be monitored closely when using oral troches, as the drug is metabolized by the liver. Topical and vaginal forms do not require adjustment.

Elderly Patients

No specific dosage adjustments are required for geriatric patients. However, healthcare providers should consider the increased prevalence of skin fragility and potential polypharmacy (use of multiple medications) in this population.

• Topical: Wash the affected area with mild soap and dry thoroughly before application. Apply a thin layer and rub in gently. Do not cover with an occlusive (airtight) dressing unless directed by your doctor.
• Vaginal: Use the provided applicator to insert the cream or tablet high into the vagina, preferably at bedtime. Wear cotton underwear and avoid using tampons or douches during treatment.
• Oral Troche: Do not chew or swallow the troche whole. Allow it to dissolve slowly in the mouth (usually takes 15-30 minutes).
• Storage: Store all forms at room temperature (15°C to 30°C / 59°F to 86°F). Protect from freezing and excessive heat.

If you miss a dose, apply or take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not double the dose to catch up.

Systemic overdose from topical or vaginal application is highly unlikely. If the oral troches are consumed in large quantities, symptoms may include nausea, vomiting, or dizziness. In case of accidental ingestion by a child, contact a Poison Control Center or emergency room immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop treatment early, even if symptoms improve, as the infection may return.

Side effects of clotrimazole are generally localized to the site of application and are mild in nature. For topical and vaginal forms, common reactions include:

• Erythema (Redness): The skin or vaginal tissue may appear slightly more red than usual.
• Stinging or Burning: A transient sensation of heat or sharp stinging immediately following application.
• Pruritus (Itching): Mild itching at the site of treatment.
• Irritation: General discomfort or a feeling of rawness in the treated area.

These effects typically resolve within a few minutes or after the first few days of treatment as the body adjusts to the medication.

• Contact Dermatitis: A localized allergic-like reaction causing a rash or small bumps.
• Skin Peeling or Flaking: As the fungal infection clears, the dead skin may peel away.
• Edema (Swelling): Minor swelling of the treated area.
• Vaginal Discharge: Increased discharge or a change in consistency when using vaginal products.
• Abdominal Cramping: Occasionally reported with vaginal use.

• Urticaria (Hives): Raised, itchy welts on the skin.
• Blistering: The formation of small fluid-filled sacs at the application site.
• Fainting or Hypotension: Extremely rare, usually associated with an undiagnosed systemic allergy.
• Liver Enzyme Elevation: This has been observed rarely in patients using oral troches for extended periods.

While clotrimazole is very safe, severe allergic reactions can occur.

> Warning: Stop taking Clotrimazole and call your doctor immediately if you experience any of these:

• Anaphylaxis: Symptoms include difficulty breathing, swelling of the face, lips, tongue, or throat, and severe dizziness.
• Severe Skin Sloughing: Extensive peeling or blistering that covers large areas of the body.
• Intense Burning: Pain that is so severe it prevents normal activity.
• Jaundice: Yellowing of the eyes or skin (specific to oral troche use, indicating potential liver stress).

Clotrimazole is intended for short-term use (usually 1 to 4 weeks). Prolonged or repetitive use without medical supervision can lead to:

• Fungal Resistance: The fungi may become less sensitive to the medication, making future infections harder to treat.
• Secondary Infections: Overgrowth of non-susceptible organisms (like certain bacteria) may occur if the natural flora is disrupted for too long.
• Skin Atrophy: While rare with antifungals compared to steroids, chronic irritation can thin the skin over time.

No FDA black box warnings for Clotrimazole. It is considered one of the safer antifungal agents available, often provided over-the-counter (OTC) for most indications.

Report any unusual symptoms to your healthcare provider. If you notice a side effect not listed here, contact the FDA at 1-800-FDA-1088.

Clotrimazole is for external or local use only. It should never be used in the eyes. If the medication comes into contact with the eyes, rinse thoroughly with cool water. Patients should be aware that while symptoms may improve within a few days, the full course of treatment must be completed to ensure the fungus is completely eradicated.

No FDA black box warnings for Clotrimazole. It has a well-established safety profile spanning over five decades of clinical use.

• Allergic Reactions: Patients with a known hypersensitivity to other azole antifungals (such as fluconazole, ketoconazole, or miconazole) should use clotrimazole with caution, as cross-sensitivity may occur.
• Vaginal Health: Vaginal clotrimazole products may damage latex-based contraceptives, such as condoms and diaphragms. This reduces their effectiveness in preventing pregnancy and sexually transmitted infections (STIs). Patients should use alternative contraceptive methods during treatment and for at least 3 days after treatment ends.
• Underlying Conditions: If a patient has a fever, chills, or foul-smelling vaginal discharge, they should consult a doctor before using OTC clotrimazole, as these may be signs of a more serious infection like Pelvic Inflammatory Disease (PID).
• Oral Troche Risks: Patients with xerostomia (dry mouth) may find it difficult to dissolve the troche, reducing its efficacy. Additionally, the troche contains sugar, which should be considered by patients with diabetes.

• Liver Function: For patients on long-term oral troche therapy (e.g., immunocompromised patients), periodic liver function tests (AST, ALT, Bilirubin) may be recommended by a healthcare provider.
• Clinical Response: If there is no improvement after 4 weeks of treatment for athlete's foot or ringworm, or after 1 week for a yeast infection, the diagnosis should be re-evaluated by a clinician.

Clotrimazole has no known effect on the ability to drive or operate heavy machinery. It does not cause sedation or cognitive impairment.

There are no direct contraindications regarding alcohol use with topical or vaginal clotrimazole. However, for oral troches, alcohol may exacerbate potential liver stress or cause local irritation to the oral mucosa already sensitized by a fungal infection.

There is no withdrawal syndrome associated with stopping clotrimazole. However, premature discontinuation is the leading cause of treatment failure and recurrent infections. Always complete the prescribed duration.

> Important: Discuss all your medical conditions with your healthcare provider before starting Clotrimazole, especially if you have a history of liver disease or are immunocompromised.

Because topical and vaginal clotrimazole have minimal systemic absorption, there are no absolute drug-drug contraindications for these forms. However, for the oral troche, the following should be avoided:

• Cisapride: Clotrimazole may inhibit the metabolism of cisapride, leading to increased levels and a risk of serious cardiac arrhythmias (QT prolongation).

• Tacrolimus and Sirolimus: Oral clotrimazole (troche) can inhibit the CYP3A4 enzyme system in the liver. This may lead to significantly increased blood levels of immunosuppressants like tacrolimus, increasing the risk of nephrotoxicity (kidney damage). Blood levels of these drugs must be monitored closely if used concurrently.
• Warfarin: There have been rare reports of increased INR (International Normalized Ratio) and bleeding risk in patients using vaginal clotrimazole while on warfarin. Patients on anticoagulants should be monitored for signs of bruising or bleeding.

• Nystatin or Amphotericin B: These are other antifungal agents. When used together with clotrimazole, they may exhibit antagonistic effects (working against each other), potentially reducing the efficacy of both medications.
• Dexamethasone: High doses of steroids may reduce the effectiveness of clotrimazole by suppressing the local immune response or altering the fungal environment.

• Sugar Content: Each oral troche contains approximately 0.9 grams of dextrose. While this is a small amount, patients with poorly controlled diabetes should be mindful of the total daily intake if using the troche five times a day.
• Grapefruit Juice: While primarily a concern for systemic azoles, grapefruit juice can inhibit CYP3A4. It is unlikely to affect topical clotrimazole but could theoretically increase the systemic exposure of oral troches.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4. It may speed up the metabolism of any absorbed clotrimazole, potentially reducing its effectiveness, though the clinical significance for a local treatment is low.

Clotrimazole does not typically interfere with standard blood or urine laboratory tests. However, it may interfere with certain fungal culture results if the sample is taken while the medication is still present on the skin or in the vagina.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Even topical medications can sometimes interact with systemic drugs.

Clotrimazole must NEVER be used in the following circumstances:

• Hypersensitivity: Any patient with a known, documented allergy to clotrimazole or any other component of the formulation (such as cetostearyl alcohol or polysorbate 80) must avoid its use. An allergic reaction could lead to contact dermatitis or, in extreme cases, anaphylaxis.
• Ophthalmic Use: Clotrimazole is not formulated for the eyes. Accidental application can cause severe corneal irritation or chemical burns.

Conditions requiring careful risk-benefit analysis include:

• First Trimester of Pregnancy: While studies have not shown harm, many clinicians prefer to avoid vaginal inserts during the first trimester unless absolutely necessary, opting for topical creams only.
• Diabetes Mellitus: Patients with diabetes are more prone to fungal infections. If a yeast infection is recurrent (more than 4 times a year), it may be a sign of poorly controlled blood sugar rather than a simple infection, requiring a systemic medical evaluation.
• Severely Impaired Liver Function: Specifically for the oral troche, the liver's inability to process the drug may lead to accumulation, though systemic levels remain low.

Patients who have experienced a severe reaction to other imidazole antifungals—including miconazole (Monistat), ketoconazole (Nizoral), or econazole (Spectazole)—are at a higher risk of reacting to clotrimazole. This cross-sensitivity occurs because these drugs share a similar chemical structure. If you have had a rash or hives from one 'azole' drug, consult your pharmacist before using another.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Clotrimazole. Ensure they are aware of any past allergic reactions to medications.

Clotrimazole is classified as FDA Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no adequate and well-controlled studies in pregnant women.

• Topical Use: Considered safe throughout pregnancy as systemic absorption is negligible.
• Vaginal Use: Clinical data from the second and third trimesters suggest no adverse effects on the fetus. However, during the first trimester, vaginal clotrimazole should be used only if clearly needed. Healthcare providers often recommend applying the cream by hand rather than using an applicator to avoid contact with the cervix.

It is not known whether clotrimazole is excreted in human milk. However, because systemic absorption after topical or vaginal application is so low, it is considered unlikely to pose a risk to the nursing infant. If applying to the breast area for a fungal infection, the skin should be washed thoroughly before breastfeeding to prevent the infant from directly ingesting the cream.

• Approved Uses: Clotrimazole is widely used in children for diaper candidiasis and tinea infections.
• Safety: It is generally well-tolerated. Parents should ensure the child does not ingest the topical cream.
• Restrictions: Vaginal products are not for use in children under 12 without a doctor's diagnosis, as they may have different causes for vaginal irritation (e.g., hygiene issues or foreign bodies).

Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. In general, elderly patients may have thinner skin, which could theoretically increase absorption, but this has not been shown to be clinically significant. No dosage adjustment is required based on age alone.

No dosage adjustment is necessary for patients with renal impairment. The drug is primarily cleared via hepatic metabolism and fecal excretion, with less than 1% of a systemic dose excreted in the urine.

For topical and vaginal use, no adjustment is needed. For oral troches, patients with liver cirrhosis or other hepatic diseases should be monitored for elevations in liver enzymes, as the drug is metabolized by the CYP450 system.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Clotrimazole is an imidazole antifungal that works by inhibiting the enzyme lanosterol 14-alpha-demethylase. This enzyme is a member of the cytochrome P450 family and is responsible for converting lanosterol into ergosterol. Ergosterol is the primary sterol found in fungal cell membranes. By depleting ergosterol and causing the accumulation of toxic methylated sterols, clotrimazole disrupts the membrane's permeability. This leads to the leakage of intracellular components and eventual cell lysis. Furthermore, at high concentrations, clotrimazole may also inhibit fungal mitochondrial and peroxisomal enzymes, leading to a toxic buildup of hydrogen peroxide within the fungal cell.

Clotrimazole is primarily fungistatic (inhibits growth) but can be fungicidal (kills fungi) at higher concentrations or against specific organisms. The onset of action for symptom relief (itching/burning) is typically within 24 to 48 hours, though the infection itself takes longer to clear. It has a broad spectrum of activity, covering most Candida species and dermatophytes.

| Parameter | Value |

|---|---|

| Bioavailability | Topical: <0.5%; Vaginal: 3-10% |

| Protein Binding | ~90% (if systemically absorbed) |

| Half-life | 3.5 - 5 hours |

| Tmax | 2 - 6 hours (Vaginal) |

| Metabolism | Hepatic (CYP3A4) |

| Excretion | Fecal (>90%), Renal (<1%) |

• Molecular Formula: C22H17ClN2
• Molecular Weight: 344.8 g/mol
• Solubility: Practically insoluble in water; soluble in ethanol and chloroform.
• Structure: It consists of a trityl group attached to an imidazole ring, with a chlorine atom on one of the phenyl rings.

Clotrimazole belongs to the Imidazole class of antifungals. Related medications include miconazole, ketoconazole, and oxiconazole. It is distinct from the Triazole class (e.g., fluconazole, itraconazole), which generally has better systemic absorption and is used for internal infections.